Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Baldwin Group $1.006 billion credit facilities financing
We advised the borrower on the refinancing and amendment
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Norwegian Cruise Line Holdings comprehensive refinancing transactions
The transactions included new debt, exchangeable debt, registered direct equity offerings and concurrent tender offers
Bombardier $250 million senior notes offering
The investment-grade senior notes are due 2033
Natura sale of Avon International to Regent
We are advising Natura on the sale
Century Communities $500 million senior notes offering and concurrent redemption
The high-yield notes are due 2033
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Strive Nasdaq listing and $450 million at-the-market offering
We advised Strive on its Nasdaq listing and offering
Enovix $360 million convertible senior notes and capped call transactions
The 4.75% convertible notes are due 2030
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055